The new V4.2.0 update to both digital health programs are intended to improve user engagement, lower barriers to behavioral change and to streamline the experience and process efficiency for both users and their coaches, the Israel-based company said.
DarioHealth said that its first goal is driving stronger user engagement through making its user application and coaching platform more intuitive and personalized. The company said that those improvements will in turn lower psychological barriers to change.
The company said that many functions of the programs are new or redesigned, including new graphic intuitive tools, contextual progress alerts, additional educational content, interactive troubleshooting, enhanced in-app reports and a revised algorithm for rating and review.
“With these latest improvements, Dario pushes the boundaries of the user experience for both the patient and her provider, allowing for additional content, more engagement and a more meaningful dialogue. Dario demonstrates its commitment as a leading Digital Therapeutics solution to achieve the best outcomes and everyday quality of life in a personalized way and in a sustainable manner,” CEO Erez Raphael said in a press release.
Last month, DarioHealth said that it inked a joint marketing agreement with Glytec through which DarioHealth’s smart glucose meter will be able to transmit information to Glytec’s Glucommander Outpatient software.
At DeviceTalks Boston, Tyler Shultz will give attendees an inside look at Theranos and how he was able to sound the alarm after he realized the company was falling apart. Shultz will take attendees behind the story that everyone is talking about: the rise and fall of Elizabeth Holmes and her diagnostic company, Theranos.
Join Shultz and 1,000+ medical device professionals at the 8th annual DeviceTalks Boston.